TITLE

Effect of Oral Treatment with Pantethine on Platelet and Plasma Phospholipids in Ha Hyperlipoproteinemia

AUTHOR(S)
Prisco, Domenico; Rogasi, Pier Giorgio; Matucci, Marzia; Paniccia, Rita; Abbate, Rosanna; Gensini, Gian Franco; Semeri, Gian Gastone Neri
PUB. DATE
March 1987
SOURCE
Angiology;Mar1987, Vol. 38 Issue 3, p241
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In a single-blind, crossover, completely randomized study, the effects of oral treatment with pantethine or placebo on fatty acid composition of plasma and platelet phospholipids were investigated in 10 IIa hyperlipoproteinemic patients. A significant decrease of total cholesterol and total phospholipids was observed both in plasma and in platelets after a twenty-eight-day treatment. In plasma, pantethine induced a decrease of the ratio sphingomyelin/phosphatidylcholine. Moreover, a relative increase of n3-polyunsaturated fatty acids both in plasma and in platelet phospholipids and a decrease of arachidonic acid in plasma phospholipids were observed. These results indicate that pantethine can affect plasma and platelet lipid composition with possibly favorable influences on the determinants of cell membrane fluidity.
ACCESSION #
16352459

 

Related Articles

  • Primary Type V Hyperlipoproteinemia. Greenberg, Barry H.; Blackwelder, William C.; Levy, Robert I. // Annals of Internal Medicine;Nov77, Vol. 87 Issue 5, p526 

    Presents information on a study which described the clinical and biochemical characteristics of kindreds that were identified through propositi with primary type V hyperlipoproteinemia Methods; Results; Discussion.

  • Management of Type IV Hyperlipoproteinemia. Smith, L. Kent; Luepker, Russell V.; Rothchild, Sarah S.; Gillis, Albert; Kochman, Leon; Warbasse, J. Richard // Annals of Internal Medicine;Jan76, Vol. 84 Issue 1, p22 

    Presents a study which examined the clinical approaches for the management of type IV hyperlipoproteinemia. Association of lipoprotein diseases, particulary type IV hyperlipoproteinemia with atherosclerotic disease; Methods; Results and discussion.

  • Hyperlipoproteinemia: Problems in Diagnosis and Challenges Posed by the "Type III" Disorder.  // Annals of Internal Medicine;Feb75, Vol. 82 Issue 2, p273 

    Editorial. Presents an article on the examination of the incidence of type III hyperlipoproteinemia. Information on the electrophoresis of lipoproteins in relation to the disease; Description of patients with the disease.

  • Nutritional & Pharmacologic Management of Hyperlipoproteinemia. Edward Pickering, J. // Angiology;Sep1982, Vol. 33 Issue 9, p577 

    The results of the nutritional intervention on one of the twenty MRFIT centers is presented. The reduction in cholesterol was 5.78% after four years. Those results were compared with the changes found in serum cholesterol with a similar diet and the administration of either clofibrate or...

  • Cholestyramine in Type II Hyperlipoproteinemia. Levy, R.I.; Frederickson, D.S.; Stone, N.J.; Bilheimer, D.W.; Brown, W.V.; Glueck, C.J.; Gotto, A.M.; Herbert, P.N.; Kwiterovich, P.O.; Langer, T.; LaRosa, J.; Lux, S.E.; Rider, A.K.; Schulman, R.S.; Sloan, H.R. // Annals of Internal Medicine;Jul73, Vol. 79 Issue 1, p51 

    Presents a study which examined the efficacy of chlorestyramine in the treatment of type II hyperlipoproteinemia. Patients and methods; Results; Discussion.

  • Hyperlipoproteinemia.  // Diseases & Disorders: A Nursing Therapeutics Manual, 2nd edition;2002, p471 

    Provides information on hyperlipoproteinemia, a condition characterized by increased lipids in the blood that causes decreased rate of lipoprotein breakdown. Types of hyperlipoproteinemia; Causes of hyperlipoproteinemia; Diagnosis and clinical management of hyperlipoproteinemia.

  • Dyslipidemia and Eye Diseases in the Adult Chinese Population: The Beijing Eye Study. Shuang Wang; Liang Xu; Jost B. Jonas; Ya Xing Wang; Qi Sheng You; Hua Yang // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    To determine associations between dyslipidemia and ocular diseases, the population-based Beijing Eye Study 2006 examined 3251 subjects (age&⩽x2A7E;45 years) who underwent a detailed ophthalmic examination and biochemical blood analysis. Dyslipidemia was defined as any of the following:...

  • Dyslipidemia and Eye Diseases in the Adult Chinese Population: The Beijing Eye Study. Shuang Wang; Liang Xu; Jost B. Jonas; Ya Xing Wang; Qi Sheng You; Hua Yang // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    To determine associations between dyslipidemia and ocular diseases, the population-based Beijing Eye Study 2006 examined 3251 subjects (age&⩽x2A7E;45 years) who underwent a detailed ophthalmic examination and biochemical blood analysis. Dyslipidemia was defined as any of the following:...

  • Dyslipidemia and Eye Diseases in the Adult Chinese Population: The Beijing Eye Study. Shuang Wang; Liang Xu; Jost B. Jonas; Ya Xing Wang; Qi Sheng You; Hua Yang // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    To determine associations between dyslipidemia and ocular diseases, the population-based Beijing Eye Study 2006 examined 3251 subjects (age&⩽x2A7E;45 years) who underwent a detailed ophthalmic examination and biochemical blood analysis. Dyslipidemia was defined as any of the following:...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics